Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast plus salmeterol versus salmeterol alone in COPD over 52 weeks
2004-004442-40Phase 3Completed
- Sponsor
- Altana Pharma
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of roflumilast in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Altana Pharma. Primary endpoint: Change in post-bronchodilator FEV1. Started Feb 2005; status: completed.
02
Drugs
roflumilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2004-004442-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004442-40.